The bottom line: Scientists want to target senescent cells, but deciding which cells to target and how to measure the effects remains difficult. A new SENESCENCE2030 consensus roadmap calls for clearer classifications, useful biomarkers and a path toward precision medicine. It is a research agenda, not a clinical trial or proof that senolytics extend human lifespan.
A roadmap, not a treatment breakthrough
The September 3 meeting report in Nature Aging grew out of the SENESCENCE2030 conference and industry-academia workshop held in Coimbra, Portugal, in May 2026. Researchers, clinicians, industry representatives and policy stakeholders identified priorities for moving cellular senescence research into clinical practice.
SENESCENCE2030 is a multidisciplinary research network supported by COST, European Cooperation in Science and Technology. Its mission is to connect expertise in senescence, aging and age-related disease. It is not a drug, a commercial treatment program or a promise that a therapy will arrive by 2030.
Why these cells are attracting attention
Cellular senescence is often described as a durable stop to cell division after stress or damage. These cells can remain metabolically active and influence surrounding tissue. Their signals can be useful in some settings and harmful in others, which makes the popular description of senescent cells as simply unwanted “zombie cells” misleading.
As the 2024 guidelines for senescence experiments in living organisms explain, translating this biology requires careful characterization of cells and their context. Evidence about the functional consequences of senescent-cell accumulation is stronger in mice than in human samples. Finding a marker in an older person’s tissue does not, by itself, establish that those cells caused a disease or should be removed.
The measurement problem
There is no universal label that reliably separates every senescent cell from every other cell. The SenNet detection recommendations, a separate expert effort cited by the roadmap, describe why: commonly used markers can appear in non-senescent cells and can be missing from senescent cells in particular contexts.
Researchers often examine p16 or p21, proteins involved in restraining cell division, alongside other clues such as DNA damage, altered lysosomal activity or secreted inflammatory signals. None is a stand-alone identity test. SenNet recommends looking for multiple hallmarks in the same cell, with attention to the tissue and cell type.
That matters because senescence is heterogeneous. Different cells can enter different states and produce different signals. A bulk tissue measurement may blur those distinctions. A blood marker may be convenient to collect without revealing exactly which cells or organs produced it. Counting a signal is not necessarily the same as counting a biologically meaningful target.
From a label to precision medicine
The roadmap calls for functional classifications of senescent states, standardized and clinically actionable biomarkers, precision senescence medicine, stronger translational and regulatory frameworks, and international collaboration.
In practical terms, a functional classification would ask what a cell state does, not just whether a familiar marker is present. Precision medicine would then aim to match an intervention to a defined biological problem in a particular patient and tissue. These are proposed directions, not an established clinical classification or a validated patient-selection test.
The clinical questions are concrete: Does a test give consistent results across laboratories? Does it identify people likely to benefit? Can it show that a treatment reached its intended target? And does that change predict better health? A biomarker that answers one question does not automatically answer all four.
Why this matters for senolytics
Senolytics aim to selectively eliminate senescent cells. Other senotherapeutic approaches seek to modify senescence-associated behavior or signaling. For either strategy, poor target definition can make a trial difficult to interpret: a disappointing outcome might reflect the intervention, the selected patients, the measurements or several problems together.
A 2024 randomized phase 2 trial illustrates the stakes. In 60 postmenopausal women, intermittent dasatinib plus quercetin did not improve the primary bone-resorption marker endpoint at 20 weeks compared with control. Exploratory analyses suggested different responses among women with higher baseline T-cell p16 expression. Those subgroup findings generated a hypothesis for further testing, not a validated rule for prescribing senolytics. The trial did not test lifespan extension.
The Lifespan Brief assessment
The unresolved work is both biological and practical. Researchers need to determine which states matter in which diseases, distinguish useful responses from damaging persistence, and establish how to measure intervention effects in people. Translational and regulatory planning must connect those measurements with safety monitoring and outcomes patients actually experience.
The roadmap’s value will depend on what follows: reproducible tests, clearly defined targets and well-designed human studies. Better measurement could help promising treatments advance and weak ideas fail sooner. Neither outcome should be confused with evidence that senolytics are proven anti-aging treatments.
Sources and reporting note
This article uses the publicly available summary of the SENESCENCE2030 meeting report for its stated priorities; the full report is subscription-only. Scientific background and the human-trial example are drawn from the separately linked primary publications above. The explanations of practical clinical questions are The Lifespan Brief’s analysis, not a claim that the roadmap has already resolved them.